<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36655353</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0253-9624</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>06</Day></PubDate></JournalIssue><Title>Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]</Title><ISOAbbreviation>Zhonghua Yu Fang Yi Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Analysis of enterovirus infection type among acute respiratory tract infection cases in Luohe City, Henan Province from 2017 to 2021].</ArticleTitle><Pagination><StartPage>378</StartPage><EndPage>385</EndPage><MedlinePgn>378-385</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112150-20221011-00985</ELocationID><Abstract><AbstractText><b>Objective:</b> To understand the infection status of Enterovirus (EV) in cases of acute respiratory infections (ARIs) in Luohe City, Henan Province from 2017 to 2021, and analyze the prevalence and type composition of EV in ARIs. <b>Methods:</b> From October 2017 to May 2021, pharyngeal swab samples were collected from 1 828 patients with ARIs in Luohe Central Hospital and the clinical epidemiological data of these cases were also collected. EV-positive samples were identified by Quantitative Real-time Polymerase Chain Reaction (qPCR). The 5'-untranslated region (5'UTR) was amplified by Reverse Transcription-Polymerase Chain Reaction (RT-PCR). The results of 5'UTR region were initially typed by Enterovirus Genotyping Tool Version 1.0. Based on the typing results, the full-length of VP1 region was amplified by RT-PCR. The EV typing was identified again by VP1 region. <b>Results:</b> Among 1 828 cases of ARIs, 56.7% (1 036) were males. The median (<i>Q</i><sub>1</sub>, <i>Q</i><sub>3</sub>) age was about 3 (1, 5) years. Patients under 5 years old accounted for 71.6% (1 309 cases). Among all cases, a total of 71 EV-positive samples were identified by qPCR, with a detection rate of 3.88% (71/1 828). The EV detection rates for men and women were 3.28% (34/1 036) and 4.67% (37/792), without statistically significant differences (<i>χ</i><sup>2</sup>=2.32, <i>P</i>=0.14). The EV detection rates for 2 to &lt;6 years, 6 months to &lt;2 years, 6 to &lt;10 years, and &lt;6 months were 6.29% (48/763), 3.00% (18/600), 2.52% (4/159), and 1.67% (1/60) (<i>χ</i><sup>2</sup>=27.91, <i>P</i>&lt;0.001). The EV detection rate was 0.92% (3/326) in autumn and winter of 2017. The EV detection rates were 1.18% (6/508), 2.47% (12/485) and 8.31% (34/409) in each year from 2018 to 2020, with an increasing trend year by year(<i>χ</i><sup>2</sup><sub>trend</sub>=29.76, <i>P</i>&lt;0.001). The main prevalent seasons were summer and autumn. The detection rate in spring of 2021 was 4.00% (4/100). A total of 12 types were identified and classified as CVA2, CVA4, CVA5, CVA6, CVA10, CVB3, CVB5, E5, E11, E30, PV-1, and EV-D68. The types of CVA2, CVA10, CVA6, and CVB3 were the dominant phenotypes. In 59 sample of EV typing, the main clinical manifestation was upper respiratory tract infection (36/59, 61.01%). The dominant types detected in upper respiratory tract infections were CVA10 (10/36, 27.78%), CVA6 (9/36, 25.00%) and CVB3 (8/36, 22.22%). The dominant type detected in lower respiratory tract infections was CVA2 (7/19, 36.84%). <b>Conclusion:</b> In Luohe City, Henan Province from 2017 to 2021, EV infection in ARIs cases has clear seasonal and age-specific patterns, and the dominant types of upper and lower respiratory tract infections are different.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>W X</ForeName><Initials>WX</Initials><AffiliationInfo><Affiliation>School of Public Health and Health Management, Shandong First Medical University/Shandong Academy of Medical Sciences, Jinan 250117, China NHC Key Laboratory of Medical Virology and Viral Diseases/National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Z B</ForeName><Initials>ZB</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Medical Virology and Viral Diseases/National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Expanded Immunization Programme, Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>B C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Medical Virology and Viral Diseases/National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>H J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>School of Public Health and Health Management, Shandong First Medical University/Shandong Academy of Medical Sciences, Jinan 250117, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>J H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Medical Virology and Viral Diseases/National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>H L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Medical Virology and Viral Diseases/National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>W W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Medical Virology and Viral Diseases/National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Medical Virology and Viral Diseases/National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Public Health and Health Management, Shandong First Medical University/Shandong Academy of Medical Sciences, Jinan 250117, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZDGW21‑131031103000180005</GrantID><Agency>Chinese National Health Commission Major Public Health Project</Agency><Country /></Grant><Grant><GrantID>ZDGW21-131031103000180005</GrantID><Agency>Chinese National Health Commission Major Public Health Project</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Yu Fang Yi Xue Za Zhi</MedlineTA><NlmUniqueID>7904962</NlmUniqueID><ISSNLinking>0253-9624</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020121">5' Untranslated Regions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020121" MajorTopicYN="N">5' Untranslated Regions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>目的：</b> 了解2017—2021年河南省漯河市急性呼吸道感染（ARIs）病例中肠道病毒（EV）的感染状况，分析EV在ARIs中的流行情况及型别组成。 <b>方法：</b> 于2017年10月至2021年5月，采集河南省漯河市中心医院1 828例ARIs患者的咽拭子样本，并收集相关临床流行病学资料。采用实时荧光定量聚合酶链式反应（qPCR）筛选EV阳性样本，随后对阳性样本采用反转录聚合酶链式反应（RT-PCR）扩增5′非翻译区（5′UTR），使用Enterovirus Genotyping Tool在线定型工具初步定型后采用RT-PCR法进行VP1区全长扩增，再次比对确定EV分型。 <b>结果：</b> 1 828例ARIs病例中，男性占56.7%（1 036例）；年龄<i>M</i>（<i>Q</i><sub>1</sub>，<i>Q</i><sub>3</sub>）为3（1，5）岁；5岁以下人群占71.6%（1 309例）。1 828例ARIs病例中，通过qPCR检测鉴定EV阳性样本共有71例，检出率为3.88%（71/1 828）；男、女性EV检出率分别为3.28%（34/1 036）和4.67%（37/792），差异无统计学意义（<i>χ</i><sup>2</sup>=2.32，<i>P</i>=0.14）。2~&lt;6岁、6月龄~&lt;2岁、6~&lt;10岁和&lt;6月龄的EV检出率依次为6.29%（48/763）、3.00%（18/600）、2.52%（4/159）和1.67%（1/60）（<i>χ<sup>2</sup></i>=27.91，<i>P</i>&lt;0.001）。2017年秋、冬季EV检出率为0.92%（3/326）；2018—2020年各年EV检出率依次为1.18%（6/508）、2.47%（12/485）和8.31%（34/409），呈逐年上升趋势（<i>χ</i><sup>2</sup><sub>趋势</sub>=29.76，<i>P</i>&lt;0.001），主要流行季节为夏、秋季；2021年春季检出率为4.00%（4/100）。共鉴定出12种型别：CVA2、CVA4、CVA5、CVA6、CVA10、CVB3、CVB5、E5、E11、E30、PV-1和EV-D68，其中CVA2、CVA10、CVA6和CVB3为优势型别。59例EV分型样本中，临床表现以上呼吸道感染为主（36/59，61.01%）。上呼吸道感染检出的优势型别为CVA10（10/36，27.78%）、CVA6（9/36，25.00%）和CVB3（8/36，22.22%）；下呼吸道感染中检出的优势型别为CVA2（7/19，36.84%）。 <b>结论：</b> 2017—2021年河南省漯河市ARIs病例中EV感染具有明确的季节性和年龄特征，上、下呼吸道感染所检出的优势型别有所不同。.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>19</Day><Hour>3</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36655353</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112150-20221011-00985</ArticleId></ArticleIdList></PubmedData></PubmedArticle>